Research graph
References from Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update
10.1200/jco.22.02864 · 2023 · External reference
Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update
10.1200/jco.21.01392 · 2021 · External reference
Breast cancer statistics, 2022
10.3322/caac.21754 · 2022 · External reference
Breast cancer
10.1038/s41572-019-0111-2 · 2019 · External reference
Cancer treatment and survivorship statistics, 2025
10.3322/caac.70011 · 2025 · External reference
Unlocking the potential of antibody-drug conjugates for cancer therapy
10.1038/s41571-021-00470-8 · 2021 · External reference
Antibody-drug conjugates come of age in oncology
10.1038/s41573-023-00709-2 · 2023 · External reference
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
10.18632/oncotarget.25615 · 2018 · External reference
Evolution of TROP2: biological insights and clinical applications
10.1016/j.ejmech.2025.117863 · 2025 · External reference
Sacituzumab govitecan: first approval
10.1007/s40265-020-01337-5 · 2020 · External reference
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan
10.1080/19420862.2019.1632115 · 2019 · External reference
Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release
10.1158/1535-7163.mct-22-0375 · 2023 · External reference
First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors
10.1158/1078-0432.ccr-14-3321 · 2015 · External reference
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
10.1056/nejmoa1814213 · 2019 · External reference
A meta-analysis and systematic review of the first trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer
10.1007/s00228-025-03876-w · 2025 · External reference
Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis
10.1016/j.breast.2024.103853 · 2025 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Rob 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · 2003 · External reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · 2023 · External reference
Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
10.1038/s41591-024-03269-z · 2024 · External reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · 2025 · External reference
Leveraging TROP2 antibody-drug conjugates in solid tumors
10.1146/annurev-med-071322-065903 · 2024 · External reference
Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach
10.3390/cancers13102308 · 2021 · External reference
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
10.1016/j.ejca.2025.115451 · 2025 · External reference
Antiemetics: aSCO guideline update
10.1200/jco.20.01296 · 2020 · External reference
Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials
10.3389/fimmu.2025.1679648 · 2026 · External reference
Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer
10.1016/j.pharmthera.2022.108296 · 2022 · External reference
Trop2-targeted therapies in solid tumors: advances and future directions
10.7150/thno.98178 · 2024 · External reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · 2023 · External reference
Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer
10.1016/j.breast.2022.10.007 · 2022 · External reference
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
10.1038/s41392-022-00947-7 · 2022 · External reference
Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics
10.1016/j.heliyon.2024.e33232 · 2024 · External reference
Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics
10.1002/cncr.30789 · 2017 · External reference
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia
10.1016/j.esmoop.2026.106905 · External reference
Breaking barriers in triple negative breast cancer (TNBC) - unleashing the power of antibody-drug conjugates (ADCs)
10.1016/j.ctrv.2023.102672 · 2024 · External reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · 2026 · External reference
SACI-IO TNBC: randomized phase II trial of sacituzumab govitecan ± pembrolizumabin PD-L1- metastatic triple-negative breast cancer
10.1200/jco.2021.39.15_suppl.tps1106 · 2021 · External reference
Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics
10.1002/cncr.30789 · ExternalCitation · doi-reference
A meta-analysis and systematic review of the first trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer
10.1007/s00228-025-03876-w · ExternalCitation · doi-reference
Sacituzumab govitecan: first approval
10.1007/s40265-020-01337-5 · ExternalCitation · doi-reference
Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer
10.1016/j.breast.2022.10.007 · ExternalCitation · doi-reference
Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis
10.1016/j.breast.2024.103853 · ExternalCitation · doi-reference
Breaking barriers in triple negative breast cancer (TNBC) - unleashing the power of antibody-drug conjugates (ADCs)
10.1016/j.ctrv.2023.102672 · ExternalCitation · doi-reference
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
10.1016/j.ejca.2025.115451 · ExternalCitation · doi-reference
Evolution of TROP2: biological insights and clinical applications
10.1016/j.ejmech.2025.117863 · ExternalCitation · doi-reference
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia
10.1016/j.esmoop.2026.106905 · ExternalCitation · doi-reference
Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics
10.1016/j.heliyon.2024.e33232 · ExternalCitation · doi-reference
Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer
10.1016/j.pharmthera.2022.108296 · ExternalCitation · doi-reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · ExternalCitation · doi-reference
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
10.1038/s41392-022-00947-7 · ExternalCitation · doi-reference
Unlocking the potential of antibody-drug conjugates for cancer therapy
10.1038/s41571-021-00470-8 · ExternalCitation · doi-reference
Breast cancer
10.1038/s41572-019-0111-2 · ExternalCitation · doi-reference
Antibody-drug conjugates come of age in oncology
10.1038/s41573-023-00709-2 · ExternalCitation · doi-reference
Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
10.1038/s41591-024-03269-z · ExternalCitation · doi-reference
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
10.1056/nejmoa1814213 · ExternalCitation · doi-reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · ExternalCitation · doi-reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · ExternalCitation · doi-reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · ExternalCitation · doi-reference
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan
10.1080/19420862.2019.1632115 · ExternalCitation · doi-reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · ExternalCitation · doi-reference
Rob 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · ExternalCitation · doi-reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · ExternalCitation · doi-reference
Leveraging TROP2 antibody-drug conjugates in solid tumors
10.1146/annurev-med-071322-065903 · ExternalCitation · doi-reference
First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors
10.1158/1078-0432.ccr-14-3321 · ExternalCitation · doi-reference
Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release
10.1158/1535-7163.mct-22-0375 · ExternalCitation · doi-reference
Antiemetics: aSCO guideline update
10.1200/jco.20.01296 · ExternalCitation · doi-reference
SACI-IO TNBC: randomized phase II trial of sacituzumab govitecan ± pembrolizumabin PD-L1- metastatic triple-negative breast cancer
10.1200/jco.2021.39.15_suppl.tps1106 · ExternalCitation · doi-reference
Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update
10.1200/jco.21.01392 · ExternalCitation · doi-reference
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update
10.1200/jco.22.02864 · ExternalCitation · doi-reference
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
10.18632/oncotarget.25615 · ExternalCitation · doi-reference
Breast cancer statistics, 2022
10.3322/caac.21754 · ExternalCitation · doi-reference
Global cancer statistics 2022: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · ExternalCitation · doi-reference
Cancer treatment and survivorship statistics, 2025
10.3322/caac.70011 · ExternalCitation · doi-reference
Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials
10.3389/fimmu.2025.1679648 · ExternalCitation · doi-reference
Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach
10.3390/cancers13102308 · ExternalCitation · doi-reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · ExternalCitation · doi-reference
Trop2-targeted therapies in solid tumors: advances and future directions
10.7150/thno.98178 · ExternalCitation · doi-reference
